By Elyse Gellerman, CEO Representatives from 25 neuroendocrine cancer advocacy groups gathered earlier this month in Sofia, Bulgaria, for the 13th INCA (International Neuroendocrine Cancer
By Anna Greene, PhD, NETRF Director of Research A major new study published in JAMA Network Open by Arvind Dasari, MD, MS, and colleagues provides
By Anna Greene, PhD, NETRF Director of Research We’re excited to share insights from a new ENETS (European Neuroendocrine Tumor Society) position statement, published in
By Anne-Marie Green, NETRF Director of Digital Communications NETRF brought the NET Impact Thrivership & Research Education Program to Alabama for the first time on
By Anna Greene, PhD, NETRF Director of Research Pancreatic neuroendocrine tumors (PanNETs) are rare and tricky. Some grow slowly and never cause trouble, while others
By Anne-Marie Green, Director of Digital Communications As a 19-year veteran educator, Dr. Barbara Dunham’s learning instincts were set in motion when she was diagnosed
Congress recently passed new tax legislation that will change how charitable contributions are treated starting in 2026. While the bill is complex, we want to
We’re proud to celebrate Dr. Suzann Duan, an Assistant Professor in the Department of Pharmaceutical Sciences at UC Irvine, as the recipient of the 2025 Basic/Translational
By Anna Greene, PhD, NETRF Director of Research Dr. Benjamin Viglianti, recipient of a 2023 NETRF Investigator Award, is the senior author of a newly
NETRF is excited to announce that applications are now open for the Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs), developed in partnership with